Lonvoguran ziclumeran (lonvo-z)

Name: Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Economic burden and healthcare resource utilization
Published: 2026-09-14T15:39:06-04:00

Hereditary angioedema

Also known as NTLA-2002

Manufacturer: Intellia Therapeutics
Regulatory submission: Rolling BLA initiated April 2026 and accepted September 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Hereditary angioedema

Economic burden and healthcare resource utilization

1 evidence topic · 4 sources

Drug patterns and economic costs

“Notably, annualized expenditures for ODT prescriptions, hospitalizations, and ED visits averaged >$200,000, even after initiation of SC LTP.” (opens the source at this quote in a new tab)